ZACN
geneOn this page
Also known as LGICZL2ZACZAC1
Summary
ZACN (zinc activated ion channel, HGNC:29504) is a protein-coding gene on chromosome 17q25.1, encoding Ligand-gated cation channel ZACN (Q401N2). Ligand-gated cation channel that allows the movement of sodium and potassium monoatomic cations across cell membranes when activated by zinc (Zn2+), copper (Cu2+), and changes in pH.
LGICZ1 is a zinc-activated ligand-gated ion channel that defines a new subgroup of the cysteine-loop superfamily of ligand-gated ion channels (Davies et al., 2003 [PubMed 12381728]).
Source: NCBI Gene 353174 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 45 total
- MANE Select transcript:
NM_180990
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29504 |
| Approved symbol | ZACN |
| Name | zinc activated ion channel |
| Location | 17q25.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | LGICZ, L2, ZAC, ZAC1 |
| Ensembl gene | ENSG00000186919 |
| Ensembl biotype | protein_coding |
| OMIM | 610935 |
| Entrez | 353174 |
Gene structure
Transcript identifiers
Ensembl transcripts: 6 — 3 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding
ENST00000334586, ENST00000421794, ENST00000425015, ENST00000524242, ENST00000590045, ENST00000591500
RefSeq mRNA: 1 — MANE Select: NM_180990
NM_180990
CCDS: CCDS11740
Canonical transcript exons
ENST00000334586 — 9 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001338961 | 76080255 | 76080424 |
| ENSE00001338962 | 76079888 | 76079994 |
| ENSE00003480252 | 76082463 | 76082806 |
| ENSE00003541799 | 76081545 | 76081755 |
| ENSE00003545051 | 76079182 | 76079361 |
| ENSE00003548886 | 76081882 | 76082049 |
| ENSE00003582884 | 76081278 | 76081402 |
| ENSE00003650689 | 76079439 | 76079563 |
| ENSE00003661213 | 76079702 | 76079746 |
Expression profiles
Bgee: expression breadth ubiquitous, 162 present calls, max score 93.43.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 6.3635 / max 648.7927, expressed in 107 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 162815 | 5.3861 | 77 |
| 162816 | 0.9774 | 58 |
Top tissues by expression
245 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| right hemisphere of cerebellum | UBERON:0014890 | 93.43 | gold quality |
| right frontal lobe | UBERON:0002810 | 92.80 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 92.63 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 92.49 | gold quality |
| cerebellar cortex | UBERON:0002129 | 92.28 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 92.10 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 91.18 | gold quality |
| cortical plate | UBERON:0005343 | 90.07 | gold quality |
| cerebellum | UBERON:0002037 | 88.80 | gold quality |
| adenohypophysis | UBERON:0002196 | 88.55 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 88.53 | gold quality |
| prefrontal cortex | UBERON:0000451 | 88.04 | gold quality |
| hypothalamus | UBERON:0001898 | 87.77 | gold quality |
| apex of heart | UBERON:0002098 | 86.61 | gold quality |
| amygdala | UBERON:0001876 | 86.29 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 85.91 | gold quality |
| nucleus accumbens | UBERON:0001882 | 85.62 | gold quality |
| putamen | UBERON:0001874 | 85.19 | gold quality |
| pituitary gland | UBERON:0000007 | 85.11 | gold quality |
| caudate nucleus | UBERON:0001873 | 84.59 | gold quality |
| metanephros cortex | UBERON:0010533 | 84.51 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 84.00 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 83.95 | gold quality |
| ganglionic eminence | UBERON:0004023 | 83.92 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 83.50 | gold quality |
| right uterine tube | UBERON:0001302 | 83.30 | gold quality |
| neocortex | UBERON:0001950 | 82.34 | gold quality |
| right lobe of liver | UBERON:0001114 | 82.13 | gold quality |
| spinal cord | UBERON:0002240 | 81.81 | gold quality |
| esophagus mucosa | UBERON:0002469 | 81.36 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.17 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
8 targeting ZACN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-6739-5P | 99.80 | 67.87 | 2806 |
| HSA-MIR-6733-5P | 99.74 | 67.94 | 2759 |
| HSA-MIR-6737-3P | 98.95 | 68.56 | 1577 |
| HSA-MIR-7157-3P | 98.95 | 68.70 | 1582 |
| HSA-MIR-629-5P | 98.78 | 68.72 | 1032 |
| HSA-MIR-5008-3P | 98.73 | 67.50 | 1433 |
| HSA-MIR-5196-3P | 97.57 | 65.98 | 979 |
| HSA-MIR-4793-5P | 96.88 | 65.90 | 872 |
Literature-anchored findings (GeneRIF, showing 2)
- analysis of ligand-gated ion-channel receptor L2 in central nervous system (PMID:16083862)
- Probing the molecular basis for signal transduction through the Zinc-Activated Channel (ZAC). (PMID:34560053)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| ENSDARG00000111812 | ||
| danio_rerio | ENSDARG00000115573 | |
| ENSDARG00000115752 |
Paralogs (45): GABRA3 (ENSG00000011677), GABRA1 (ENSG00000022355), CHRNA3 (ENSG00000080644), GABRP (ENSG00000094755), CHRNA4 (ENSG00000101204), GLRA2 (ENSG00000101958), GABRE (ENSG00000102287), CHRNE (ENSG00000108556), GABRA4 (ENSG00000109158), GLRB (ENSG00000109738), GABRR2 (ENSG00000111886), GABRG2 (ENSG00000113327), CHRNB4 (ENSG00000117971), CHRNA2 (ENSG00000120903), CHRNA10 (ENSG00000129749), CHRND (ENSG00000135902), CHRNA1 (ENSG00000138435), GLRA3 (ENSG00000145451), GABRA6 (ENSG00000145863), GABRB2 (ENSG00000145864), GLRA1 (ENSG00000145888), GABRR1 (ENSG00000146276), CHRNB3 (ENSG00000147432), CHRNA6 (ENSG00000147434), HTR3B (ENSG00000149305), GABRA2 (ENSG00000151834), CHRNB2 (ENSG00000160716), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRB3 (ENSG00000166206), CHRFAM7A (ENSG00000166664), HTR3A (ENSG00000166736), CHRNA5 (ENSG00000169684), CHRNB1 (ENSG00000170175), CHRNA9 (ENSG00000174343), CHRNA7 (ENSG00000175344), HTR3C (ENSG00000178084), GABRG3 (ENSG00000182256), GABRR3 (ENSG00000183185), HTR3E (ENSG00000186038)
Protein
Protein identifiers
Ligand-gated cation channel ZACN — Q401N2 (reviewed: Q401N2)
Alternative names: Ligand-gated ion channel zinc-activated 1, Ligand-gated ion-channel receptor L2, Zinc-activated channel
All UniProt accessions (1): Q401N2
UniProt curated annotations — full annotation on UniProt →
Function. Ligand-gated cation channel that allows the movement of sodium and potassium monoatomic cations across cell membranes when activated by zinc (Zn2+), copper (Cu2+), and changes in pH. Could also transport cesium.
Subcellular location. Cell membrane.
Tissue specificity. Detected in pancreas, brain, liver, placenta, trachea, kidney, spinal cord, stomach and fetal brain. In the adult brain region expression is detected in the hippocampus, striatum, amygdala and thalamus.
Post-translational modifications. Glycosylated.
Activity regulation. Inhibited by the divalent cations magnesium and calcium.
Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.
Similarity. Belongs to the ligand-gated ion channel (TC 1.A.9) family.
Isoforms (3)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q401N2-1 | 1 | yes |
| Q401N2-2 | 2 | |
| Q401N2-3 | 3 |
RefSeq proteins (1): NP_851321* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR006201 | Neur_channel | Family |
| IPR006202 | Neur_chan_lig-bd | Domain |
| IPR018000 | Neurotransmitter_ion_chnl_CS | Conserved_site |
| IPR036719 | Neuro-gated_channel_TM_sf | Homologous_superfamily |
| IPR036734 | Neur_chan_lig-bd_sf | Homologous_superfamily |
| IPR038050 | Neuro_actylchol_rec | Homologous_superfamily |
Pfam: PF02931
Catalyzed reactions (Rhea), 2 shown:
- K(+)(in) = K(+)(out) (RHEA:29463)
- Na(+)(in) = Na(+)(out) (RHEA:34963)
UniProt features (23 total): topological domain 5, glycosylation site 4, splice variant 4, transmembrane region 4, signal peptide 1, chain 1, region of interest 1, compositionally biased region 1, disulfide bond 1, sequence variant 1
Structure
Experimental structures (PDB)
9 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 9LEZ | ELECTRON MICROSCOPY | 2.54 |
| 9LET | ELECTRON MICROSCOPY | 2.62 |
| 9LEU | ELECTRON MICROSCOPY | 2.63 |
| 8YX7 | ELECTRON MICROSCOPY | 2.8 |
| 8YX8 | ELECTRON MICROSCOPY | 2.8 |
| 9LEX | ELECTRON MICROSCOPY | 2.85 |
| 8YX6 | ELECTRON MICROSCOPY | 2.9 |
| 9LEY | ELECTRON MICROSCOPY | 2.97 |
| 9LEV | ELECTRON MICROSCOPY | 3.35 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q401N2-F1 | 78.09 | 0.44 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Disulfide bonds (1): 157–171
Glycosylation sites (4): 41, 55, 99, 170
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 30 (showing top):
BENPORATH_ES_WITH_H3K27ME3, GOBP_RESPONSE_TO_ZINC_ION, GCANCTGNY_MYOD_Q6, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_RESPONSE_TO_METAL_ION, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_TRANSPORTER_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOMF_GATED_CHANNEL_ACTIVITY, GOMF_PASSIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_MONOATOMIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_EXTRACELLULAR_LIGAND_GATED_MONOATOMIC_ION_CHANNEL_ACTIVITY
GO Biological Process (4): response to zinc ion (GO:0010043), monoatomic ion transmembrane transport (GO:0034220), monoatomic ion transport (GO:0006811), monoatomic cation transmembrane transport (GO:0098655)
GO Molecular Function (7): transmembrane signaling receptor activity (GO:0004888), extracellular ligand-gated monoatomic ion channel activity (GO:0005230), zinc ion binding (GO:0008270), ligand-gated monoatomic ion channel activity (GO:0015276), ligand-gated monoatomic cation channel activity (GO:0099094), pH-gated monoatomic ion channel activity (GO:0160128), monoatomic ion channel activity (GO:0005216)
GO Cellular Component (3): plasma membrane (GO:0005886), transmembrane transporter complex (GO:1902495), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| ligand-gated monoatomic ion channel activity | 3 |
| response to metal ion | 1 |
| monoatomic ion transport | 1 |
| transmembrane transport | 1 |
| transport | 1 |
| monoatomic cation transport | 1 |
| monoatomic ion transmembrane transport | 1 |
| signaling receptor activity | 1 |
| transition metal ion binding | 1 |
| monoatomic ion channel activity | 1 |
| ligand-gated channel activity | 1 |
| monoatomic cation channel activity | 1 |
| monoatomic ion transmembrane transporter activity | 1 |
| channel activity | 1 |
| membrane | 1 |
| cell periphery | 1 |
| membrane protein complex | 1 |
| transporter complex | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
524 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZACN | GALR2 | O43603 | 819 |
| ZACN | EXOC7 | Q9UPT5 | 791 |
| ZACN | CDHR4 | A6H8M9 | 452 |
| ZACN | SPRYD7 | Q5W111 | 440 |
| ZACN | AMZ2 | Q86W34 | 406 |
| ZACN | ZNF385C | Q66K41 | 400 |
| ZACN | ABITRAM | Q9NX38 | 386 |
| ZACN | PNMA8A | Q86V59 | 384 |
| ZACN | HSDL1 | Q3SXM5 | 383 |
| ZACN | ROPN1B | Q9BZX4 | 378 |
| ZACN | FAM81B | Q96LP2 | 370 |
| ZACN | TMTC2 | Q8N394 | 370 |
| ZACN | NHERF4 | Q86UT5 | 358 |
| ZACN | PRAMEF2 | O60811 | 356 |
| ZACN | SERAC1 | Q96JX3 | 347 |
IntAct
4 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ZACN | GPAA1 | psi-mi:“MI:0914”(association) | 0.530 |
| ZACN | FAM234B | psi-mi:“MI:0914”(association) | 0.350 |
| ZACN | NEMP1 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (170): KIAA1467 (Affinity Capture-MS), EMC1 (Affinity Capture-MS), HLA-A (Affinity Capture-MS), KIAA2013 (Affinity Capture-MS), SLC12A2 (Affinity Capture-MS), ALG9 (Affinity Capture-MS), ITGA2 (Affinity Capture-MS), MFAP3 (Affinity Capture-MS), FLVCR1 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), GPAA1 (Affinity Capture-MS), TMTC3 (Affinity Capture-MS), CCPG1 (Affinity Capture-MS), GJC1 (Affinity Capture-MS), RANBP2 (Affinity Capture-MS)
ESM2 similar proteins: A0A1B0GTW7, G7PWZ3, I6M4H4, O08852, O54766, O70174, O95838, P00545, P09483, P43021, P43681, P60852, Q02644, Q07104, Q15822, Q19AE6, Q28680, Q401N2, Q58Y75, Q5DID0, Q5IS52, Q5IS77, Q5IXF8, Q62005, Q6IE08, Q6PDE7, Q6QNU9, Q6R5J1, Q6R5P0, Q7TN88, Q7Z7M1, Q80ZD5, Q866Y9, Q8BGX3, Q8BXQ3, Q8C2S7, Q8CIP5, Q8IU80, Q8IZF5, Q8N967
Diamond homologs: Q401N2, Q866Y9
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
45 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 37 |
| Likely benign | 4 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1911 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:76072296:A:AC | donor_gain | 1.0000 |
| 17:76072297:C:CC | donor_gain | 1.0000 |
| 17:76075250:AGG:A | donor_loss | 1.0000 |
| 17:76075251:GGT:G | donor_loss | 1.0000 |
| 17:76075252:G:GG | donor_gain | 1.0000 |
| 17:76075252:GTG:G | donor_loss | 1.0000 |
| 17:76075253:T:A | donor_loss | 1.0000 |
| 17:76079559:ATGTG:A | donor_gain | 1.0000 |
| 17:76079561:GTG:G | donor_gain | 1.0000 |
| 17:76079562:TG:T | donor_gain | 1.0000 |
| 17:76079563:GG:G | donor_gain | 1.0000 |
| 17:76079563:GGT:G | donor_loss | 1.0000 |
| 17:76079564:G:A | donor_loss | 1.0000 |
| 17:76079564:G:GG | donor_gain | 1.0000 |
| 17:76079565:T:G | donor_loss | 1.0000 |
| 17:76079995:G:GG | donor_gain | 1.0000 |
| 17:76080436:G:T | donor_gain | 1.0000 |
| 17:76080449:GGT:G | donor_gain | 1.0000 |
| 17:76081683:C:G | donor_gain | 1.0000 |
| 17:76081751:GCTCA:G | donor_gain | 1.0000 |
| 17:76081880:A:AG | acceptor_gain | 1.0000 |
| 17:76081881:G:GG | acceptor_gain | 1.0000 |
| 17:76072297:CT:C | donor_gain | 0.9900 |
| 17:76072306:A:AC | donor_gain | 0.9900 |
| 17:76072307:C:CC | donor_gain | 0.9900 |
| 17:76072310:T:A | donor_gain | 0.9900 |
| 17:76072385:T:TA | donor_gain | 0.9900 |
| 17:76072386:C:A | donor_gain | 0.9900 |
| 17:76075247:GACAG:G | donor_gain | 0.9900 |
| 17:76076622:C:CA | acceptor_gain | 0.9900 |
AlphaMissense
2661 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:76079968:G:C | W116C | 0.961 |
| 17:76079968:G:T | W116C | 0.961 |
| 17:76080370:T:C | F164L | 0.959 |
| 17:76080372:C:A | F164L | 0.959 |
| 17:76080372:C:G | F164L | 0.959 |
| 17:76081293:T:C | F187S | 0.956 |
| 17:76079893:G:C | W91C | 0.950 |
| 17:76079893:G:T | W91C | 0.950 |
| 17:76081292:T:C | F187L | 0.944 |
| 17:76081293:T:G | F187C | 0.944 |
| 17:76081294:C:A | F187L | 0.944 |
| 17:76081294:C:G | F187L | 0.944 |
| 17:76080371:T:G | F164C | 0.941 |
| 17:76081686:A:C | S271R | 0.940 |
| 17:76081688:T:A | S271R | 0.940 |
| 17:76081688:T:G | S271R | 0.940 |
| 17:76079891:T:A | W91R | 0.927 |
| 17:76079891:T:C | W91R | 0.927 |
| 17:76079966:T:A | W116R | 0.926 |
| 17:76079966:T:C | W116R | 0.926 |
| 17:76081670:G:C | K265N | 0.922 |
| 17:76081670:G:T | K265N | 0.922 |
| 17:76079991:A:T | E124V | 0.921 |
| 17:76080403:T:C | F175L | 0.920 |
| 17:76080405:C:A | F175L | 0.920 |
| 17:76080405:C:G | F175L | 0.920 |
| 17:76080349:T:A | C157S | 0.919 |
| 17:76080350:G:C | C157S | 0.919 |
| 17:76080404:T:C | F175S | 0.919 |
| 17:76081391:T:C | F220L | 0.915 |
dbSNP variants (sampled 300 via entrez): RS1000579419 (17:76079848 G>A), RS1000607854 (17:76081563 G>A,T), RS1000650918 (17:76080643 A>G), RS1001156691 (17:76077516 C>A,G,T), RS1001201583 (17:76077970 G>GA,GC,GCGGAT,GT), RS1001523212 (17:76080226 G>A,C,T), RS1002050683 (17:76081195 C>T), RS1003378900 (17:76078344 T>A), RS1003541244 (17:76078050 T>G), RS1004011277 (17:76082924 G>A), RS1004369940 (17:76078765 A>G), RS1004718374 (17:76082398 C>T), RS1004920342 (17:76082103 G>A,C,T), RS1005207890 (17:76081191 T>A,C), RS1005950413 (17:76079051 G>C)
Disease associations
OMIM: gene MIM:610935 | disease phenotypes: MIM:619072
GenCC curated gene-disease
Mondo (1): neurodevelopmental disorder with seizures and brain atrophy (MONDO:0033658)
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: lgic — ZAC
Most potent curated ligand interactions (6 total), top 6:
| Ligand | Action | Affinity | Parameter |
|---|---|---|---|
| H+ | Agonist | 5.6 | pEC50 |
| TTFB | Antagonist | 5.5 | pIC50 |
| Cu2+ | Agonist | 5.4 | pEC50 |
| tubocurarine | Antagonist | 5.2 | pIC50 |
| Zn2+ | Agonist | 3.7 | pEC50 |
| Ca2+ | Antagonist | 2.03 | pIC50 |
CTD chemical–gene interactions
13 total (human), top 13 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sotorasib | affects cotreatment, increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| sodium arsenite | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| abrine | increases expression | 1 |
| licochalcone B | increases expression | 1 |
| trametinib | affects cotreatment, increases expression | 1 |
| NVP-BKM120 | affects cotreatment, increases expression | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Tubocurarine | decreases activity | 1 |
| Urethane | increases expression | 1 |
| Zinc | decreases activity | 1 |
| Okadaic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Targeted by drugs: Calcium, Copper, Tubocurarine, Zinc Ion
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): neurodevelopmental disorder with seizures and brain atrophy